Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
NCT ID: NCT05349838
Last Updated: 2024-12-24
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
140 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-11-05
Study Completion Date
2022-11-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
HIV-1 infected subjects that experience virological failure while on non nucleoside reverse-transcriptase inhibitors (NNRTIs), including those with the K103N mutation, are usually switched to a boosted Protease Inhibitor (PI)-based regimen or other antiretroviral (ARV) combinations. The same is true for subjects who need to start antiretroviral therapy and have acquired virus that is already resistant to antiretrovirals. These "second line" combinations are often associated with numerous issues that can have a potential impact on the quality of life (QoL) of these patients. Therefore a simpler and better tolerated alternative second line treatment option would be a useful tool for the clinical management of these patients.
The aim of this study is to assess the efficacy and tolerability of a dual combined therapy of Dolutegravir (DTG) 50 mg Once Daily (OD) + Rilpivirine (RPV) 25 mg OD in virologically suppressed participants with previous virological failure with NNRTIs and having the clinically significant mutation K103N. The secondary objective of the study is to assess whether a simplification of the treatment in terms of pill burden, long term metabolic toxicity and potential for drug interactions improves the QOL of the participants. The study will also evaluate DTG \& RPV concentrations in the blood plus changes in cell associated virus.
In order to compare the first line treatment (boosted PI and/or other antiretroviral combinations) and the DTG+RPV combination, two thirds of study participants will be switched to DTG+RPV immediately and receive DTG+RPV for 96 weeks. The other third will be switched after 48 weeks of continuing on their first line treatment and receive DTG+RPV for 48 weeks. All participants will then be followed up for a further 30 days. Participants will be recruited from sites across Europe, and randomised onto either arm of the study. After randomisation, participants will attend approximately 10 visits over the course of two years.
The aim of this study is to assess the efficacy and tolerability of a dual combined therapy of Dolutegravir (DTG) 50 mg Once Daily (OD) + Rilpivirine (RPV) 25 mg OD in virologically suppressed participants with previous virological failure with NNRTIs and having the clinically significant mutation K103N. The secondary objective of the study is to assess whether a simplification of the treatment in terms of pill burden, long term metabolic toxicity and potential for drug interactions improves the QOL of the participants. The study will also evaluate DTG \& RPV concentrations in the blood plus changes in cell associated virus.
In order to compare the first line treatment (boosted PI and/or other antiretroviral combinations) and the DTG+RPV combination, two thirds of study participants will be switched to DTG+RPV immediately and receive DTG+RPV for 96 weeks. The other third will be switched after 48 weeks of continuing on their first line treatment and receive DTG+RPV for 48 weeks. All participants will then be followed up for a further 30 days. Participants will be recruited from sites across Europe, and randomised onto either arm of the study. After randomisation, participants will attend approximately 10 visits over the course of two years.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
HIV-1-infection
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DTG/RPV FDC Regimen
One combined Dolutegravir 50mg /Rilpivirine 25mg FDC tablet taken orally once daily
Group Type
EXPERIMENTAL
Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy
Intervention Type
DRUG
Daily oral tablet
Continued ART Regimen
Patients will continue the current boosted PI regimen (or other antiretroviral combination) for 48 weeks. Patients will then be switched to one combined Dolutegravir/Rilpivirine FDC tablet taken orally once daily for 48 weeks.
Group Type
ACTIVE_COMPARATOR
Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy
Intervention Type
DRUG
Daily oral tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy
Daily oral tablet
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Boosted protease inhibitors or other ARV regimen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patient volunteers who meet all of the following criteria are eligible for this trial:
1. Is male or female aged 18 years or over.
2. Has documented HIV-1 infection
3. Is capable of giving informed consent
4. Is willing to comply with the protocol requirements
5. Virologically suppressed (plasma HIV-RNA \<50 copies/mL for \>24 weeks) and on a stable regimen.
6. Subjects are required to have a history of the K103N mutation (acquired or selected). Subjects who at any time have had the mutations 100I, 101E/P, 106A/M, 138K/G/Q, 181C/I/V, 188L, 190A/S/E/Q, 230L mutations are to be excluded. Other NNRTI region variants can be included. All PI and NRTI mutations are acceptable. Study sites may ask the coordinating centre for advice as required.
7. Subjects must have never failed INSTI (2 x VL \>200 \>2 weeks apart) but current regimen can include Integrase Strand Transfer Inhibitor(INSTI).
8. A female, may be eligible to enter and participate in the study if she:
a. is of non-child-bearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea without an alternative medical cause and ≥ 45 years of age) A high follicle stimulating hormone (FSH) level consistent with postmenopausal status may be used to confirm a post- menopausal state in women who are not using hormonal contraception) or hormonal replacement therapy at the discretion of the Principal Investigator. However, in the absence of 12 months of amenorrhea, a single FSH measurement alone is insufficient.
OR physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or,
OR is of child-bearing potential with a negative pregnancy test at Screening (\& baseline visit) and agrees to use one of the following methods of contraception to avoid pregnancy:
True abstinence from penile-vaginal intercourse from 2 weeks prior to administration of IP, throughout the study, and for at least 2 weeks after discontinuation of all study medications (When this is in line with the preferred and usual lifestyle of the subject.) (Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), and withdrawal are not acceptable methods of contraception.
Any intrauterine device (IUD) with published data showing that the expected failure rate is \<1% per year (not all IUDs meet this criterion, see Appendix 3 for an example listing of approved IUDs).
Male partner sterilization confirmed prior to the female subject's entry into the study, and this male is the sole partner for that subject;
Approved hormonal contraception (see appendix 4 for a listing of examples of approved hormonal contraception);
Any other method with published data showing that the expected failure rate is \<1% per year.
Any contraceptive method must be used consistently and for at least 2 weeks after discontinuation of Investigational Product (IP)
9. If a heterosexually active male, he is using effective birth control methods and is willing to continue practising these birth control methods during the trial and until follow-up visit
10. Subjects currently receiving DTG or RPV, but not both, can be included.
19. Dialysis or renal insufficiency (creatinine clearance \< 50ml/min)
20. History of decompensated liver disease (Alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal (ULN), OR ALT ≥3xULN and bilirubin ≥1.5xULN (with \>35% direct bilirubin)
21. Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
22. Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh classification (see appendix 4)
23. Opportunistic infection within 4 weeks prior to first dose of DTG plus RPV.
24. Clinical decision that a switch of antiretroviral therapy should be immediate
25. Screening blood result with any grade 3/4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed). or unconjugated hyperbilirubinaemia due to atanazavir exposure.
26. Any condition (including illicit drug use or alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with assessments or completion of the trial.
27. Women planning pregnancy or who are pregnant or breast feeding. (NB: See section 6.12 Withdrawal Criteria for guidance if pregnancy does occur).
28. Females of childbearing potential and males must be willing to use a highly effective (acceptable effective contraceptive measures are only acceptable for IMP's with unlikely human teratogenicity / fetotoxicity in early pregnancy) method of contraception (hormonal method of birth control; true abstinence). Contraceptive methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods (see Appendix 4). Such methods include:
* combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral intravaginal transdermal
* progesteron-only hormonal contraception associated with inhibition of ovulation oral injectable implantable
* Intrauterine device (IUD)
* Intrauterine hormone-releasing system ( IUS)
* bilateral tubal occlusion
* vasectomized partner
* true sexual abstinence
(NB: See section 6.12 Withdrawal Criteria for guidance if pregnancy does occur).
29. Hypersensitivity to the active substances or to any of the excipients listed below: List of excipients Tablet core • Mannitol (E421) • Magnesium stearate • Microcrystalline cellulose • Povidone (K29/32) • Sodium starch glycolate • Sodium stearyl fumarate • Lactose monohydrate • Croscarmellose sodium • Povidone (K30) • Polysorbate 20 • Silicified microcrystalline cellulose Tablet coating • Polyvinyl alcohol- part hydrolysed • Titanium dioxide (E171) • Macrogol • Talc • Iron oxide yellow (E172) Iron oxide red (E172)
1. Is male or female aged 18 years or over.
2. Has documented HIV-1 infection
3. Is capable of giving informed consent
4. Is willing to comply with the protocol requirements
5. Virologically suppressed (plasma HIV-RNA \<50 copies/mL for \>24 weeks) and on a stable regimen.
6. Subjects are required to have a history of the K103N mutation (acquired or selected). Subjects who at any time have had the mutations 100I, 101E/P, 106A/M, 138K/G/Q, 181C/I/V, 188L, 190A/S/E/Q, 230L mutations are to be excluded. Other NNRTI region variants can be included. All PI and NRTI mutations are acceptable. Study sites may ask the coordinating centre for advice as required.
7. Subjects must have never failed INSTI (2 x VL \>200 \>2 weeks apart) but current regimen can include Integrase Strand Transfer Inhibitor(INSTI).
8. A female, may be eligible to enter and participate in the study if she:
a. is of non-child-bearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea without an alternative medical cause and ≥ 45 years of age) A high follicle stimulating hormone (FSH) level consistent with postmenopausal status may be used to confirm a post- menopausal state in women who are not using hormonal contraception) or hormonal replacement therapy at the discretion of the Principal Investigator. However, in the absence of 12 months of amenorrhea, a single FSH measurement alone is insufficient.
OR physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or,
OR is of child-bearing potential with a negative pregnancy test at Screening (\& baseline visit) and agrees to use one of the following methods of contraception to avoid pregnancy:
True abstinence from penile-vaginal intercourse from 2 weeks prior to administration of IP, throughout the study, and for at least 2 weeks after discontinuation of all study medications (When this is in line with the preferred and usual lifestyle of the subject.) (Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), and withdrawal are not acceptable methods of contraception.
Any intrauterine device (IUD) with published data showing that the expected failure rate is \<1% per year (not all IUDs meet this criterion, see Appendix 3 for an example listing of approved IUDs).
Male partner sterilization confirmed prior to the female subject's entry into the study, and this male is the sole partner for that subject;
Approved hormonal contraception (see appendix 4 for a listing of examples of approved hormonal contraception);
Any other method with published data showing that the expected failure rate is \<1% per year.
Any contraceptive method must be used consistently and for at least 2 weeks after discontinuation of Investigational Product (IP)
9. If a heterosexually active male, he is using effective birth control methods and is willing to continue practising these birth control methods during the trial and until follow-up visit
10. Subjects currently receiving DTG or RPV, but not both, can be included.
19. Dialysis or renal insufficiency (creatinine clearance \< 50ml/min)
20. History of decompensated liver disease (Alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal (ULN), OR ALT ≥3xULN and bilirubin ≥1.5xULN (with \>35% direct bilirubin)
21. Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
22. Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh classification (see appendix 4)
23. Opportunistic infection within 4 weeks prior to first dose of DTG plus RPV.
24. Clinical decision that a switch of antiretroviral therapy should be immediate
25. Screening blood result with any grade 3/4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed). or unconjugated hyperbilirubinaemia due to atanazavir exposure.
26. Any condition (including illicit drug use or alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with assessments or completion of the trial.
27. Women planning pregnancy or who are pregnant or breast feeding. (NB: See section 6.12 Withdrawal Criteria for guidance if pregnancy does occur).
28. Females of childbearing potential and males must be willing to use a highly effective (acceptable effective contraceptive measures are only acceptable for IMP's with unlikely human teratogenicity / fetotoxicity in early pregnancy) method of contraception (hormonal method of birth control; true abstinence). Contraceptive methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods (see Appendix 4). Such methods include:
* combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral intravaginal transdermal
* progesteron-only hormonal contraception associated with inhibition of ovulation oral injectable implantable
* Intrauterine device (IUD)
* Intrauterine hormone-releasing system ( IUS)
* bilateral tubal occlusion
* vasectomized partner
* true sexual abstinence
(NB: See section 6.12 Withdrawal Criteria for guidance if pregnancy does occur).
29. Hypersensitivity to the active substances or to any of the excipients listed below: List of excipients Tablet core • Mannitol (E421) • Magnesium stearate • Microcrystalline cellulose • Povidone (K29/32) • Sodium starch glycolate • Sodium stearyl fumarate • Lactose monohydrate • Croscarmellose sodium • Povidone (K30) • Polysorbate 20 • Silicified microcrystalline cellulose Tablet coating • Polyvinyl alcohol- part hydrolysed • Titanium dioxide (E171) • Macrogol • Talc • Iron oxide yellow (E172) Iron oxide red (E172)
Exclusion Criteria
Patients meeting 1 or more of the following criteria cannot be selected:
1. Infected with HIV-2
2. Detectable HIV-1 RNA at screening (HIV-1 RNA measurement \>=50 c/mL).
3. Subjects requiring regular dosing doing with H2 or PPI antacid medications or a history of achlorhidria or drug known to interact with RPV or DTG.
4. Use of medications which are associated with Torsades de Pointes
5. Corrected QT interval (QTc \[Bazett\]) \>450 milliseconds or QTc (Bazett) \>480 milliseconds for participants with bundle branch block. The QTc is the QT interval corrected for heart rate according to Bazett's formula (QTcB).
6. Unstable health conditions (i.e. opportunistic infections, cancers, unstable liver disease etc).
7. Any evidence of an active Centers for Disease Control and Prevention Category C disease. Exceptions include cutaneous Kaposi's sarcoma not requiring systemic therapy and historic CD4+ lymphocyte counts of \<200 cells/millimeter3.
8. History or presence of allergy to the study drugs or their components or drugs of their class;
9. Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the subject prior to randomization;
10. Any pre-existing physical or mental condition which, in the opinion of the Investigator, may interfere with the subject's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participants. Subjects considered to pose a significant risk of suicide should be excluded.
11. Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the subject unable to take oral medication;
12. Using any concomitant therapy disallowed as per the reference safety information and product labelling for the study drugs. Specifically, co-administration with the following medicinal products is not allowed:
* dofetilide or pilsicainide;
* fampridine (also known as dalfampridine);
* carbamazepine, oxcarbazepine, phenobarbital, phenytoin;
* rifampicin, rifapentine;
* proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole; - systemic dexamethasone, except as a single dose treatment;
* St John's wort (Hypericum perforatum).
13. Has acute viral hepatitis including, but not limited to, A, B, or C
14. Active hepatitis B/ Hep B non-immune subjects who have failed vaccination (antibody concentration \< 10 international units). (If local practice does not include vaccination of low risk patients, then the patients without HBsAb are not excluded - this must be clearly documented in the medical records and eCRF). (Note: subjects can be re screened if they receive vaccination and subsequently meet eligibility criteria)
15. Evidence of Hepatitis B virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), and Hepatitis B surface antibody (HBsAb) as follows: Participants positive for HBsAg are excluded; Participants positive for anti-HBc (negative HBsAg status) and negative for HBsAb are excluded. (if local practice does not include vaccination of low risk patients, then the patients without HBsAb are not excluded - this must be clearly documented in the medical records and eCRF. Note: Subject positive for anti-HBc (negative HBsAg status) and positive for HBsAb are immune to HBV and are not excluded.
16. Participants with an anticipated need for any Hepatitis C virus (HCV) therapy during the Early Switch Phase and for interferon-based therapy for HCV throughout the entire study period.
17. Any investigational drug within 30 days prior to the trial drug administration
1. Infected with HIV-2
2. Detectable HIV-1 RNA at screening (HIV-1 RNA measurement \>=50 c/mL).
3. Subjects requiring regular dosing doing with H2 or PPI antacid medications or a history of achlorhidria or drug known to interact with RPV or DTG.
4. Use of medications which are associated with Torsades de Pointes
5. Corrected QT interval (QTc \[Bazett\]) \>450 milliseconds or QTc (Bazett) \>480 milliseconds for participants with bundle branch block. The QTc is the QT interval corrected for heart rate according to Bazett's formula (QTcB).
6. Unstable health conditions (i.e. opportunistic infections, cancers, unstable liver disease etc).
7. Any evidence of an active Centers for Disease Control and Prevention Category C disease. Exceptions include cutaneous Kaposi's sarcoma not requiring systemic therapy and historic CD4+ lymphocyte counts of \<200 cells/millimeter3.
8. History or presence of allergy to the study drugs or their components or drugs of their class;
9. Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the subject prior to randomization;
10. Any pre-existing physical or mental condition which, in the opinion of the Investigator, may interfere with the subject's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participants. Subjects considered to pose a significant risk of suicide should be excluded.
11. Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the subject unable to take oral medication;
12. Using any concomitant therapy disallowed as per the reference safety information and product labelling for the study drugs. Specifically, co-administration with the following medicinal products is not allowed:
* dofetilide or pilsicainide;
* fampridine (also known as dalfampridine);
* carbamazepine, oxcarbazepine, phenobarbital, phenytoin;
* rifampicin, rifapentine;
* proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole; - systemic dexamethasone, except as a single dose treatment;
* St John's wort (Hypericum perforatum).
13. Has acute viral hepatitis including, but not limited to, A, B, or C
14. Active hepatitis B/ Hep B non-immune subjects who have failed vaccination (antibody concentration \< 10 international units). (If local practice does not include vaccination of low risk patients, then the patients without HBsAb are not excluded - this must be clearly documented in the medical records and eCRF). (Note: subjects can be re screened if they receive vaccination and subsequently meet eligibility criteria)
15. Evidence of Hepatitis B virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), and Hepatitis B surface antibody (HBsAb) as follows: Participants positive for HBsAg are excluded; Participants positive for anti-HBc (negative HBsAg status) and negative for HBsAb are excluded. (if local practice does not include vaccination of low risk patients, then the patients without HBsAb are not excluded - this must be clearly documented in the medical records and eCRF. Note: Subject positive for anti-HBc (negative HBsAg status) and positive for HBsAb are immune to HBV and are not excluded.
16. Participants with an anticipated need for any Hepatitis C virus (HCV) therapy during the Early Switch Phase and for interferon-based therapy for HCV throughout the entire study period.
17. Any investigational drug within 30 days prior to the trial drug administration
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ViiV Healthcare
INDUSTRY
Sponsor Role
collaborator
NEAT ID Foundation
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Tropical Medecine
Antwerp, , Belgium
Site Status
St Pierre University Hospital
Brussels, , Belgium
Site Status
CHU Hotel Dieu
Nantes, , France
Site Status
Hospital Saint Louis
Paris, , France
Site Status
Pitié-salpêtrière Hospital
Paris, , France
Site Status
University Bonn
Bonn, , Germany
Site Status
University Essen
Essen, , Germany
Site Status
Frankfurt University Hospital
Frankfurt, , Germany
Site Status
ICH Study Center, Hamburg
Hamburg, , Germany
Site Status
AAST delgi spedali civili di Brescia
Brescia, , Italy
Site Status
ASST FBF SACCO- I Division of Infectious Diseases 1
Milan, , Italy
Site Status
ASST FBF SACCO- I Division of Infectious Diseases 3
Milan, , Italy
Site Status
I.R.C.C.S San Raffaele Hospital
Milan, , Italy
Site Status
ASST GOM Niguarda Milano, Dep. Infectious Disease
Milan, , Italy
Site Status
Hospital General Universitario de Alicante
Alicante, , Spain
Site Status
Hospital Clínic de Barcelona
Barcelona, , Spain
Site Status
Hospital Universitari Vall d'Herbo
Barcelona, , Spain
Site Status
Infectious Diseases Unit Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Site Status
Hospital General Universitario de Elche
Elche, , Spain
Site Status
Hospital Universitario La Paz, Madrid
Madrid, , Spain
Site Status
Brighton & Sussex University NHS Trust
Brighton, , United Kingdom
Site Status
North Bristol NHS Trust, Southmead Hospital
Bristol, , United Kingdom
Site Status
Chelsea & Westminster Hospital
London, , United Kingdom
Site Status
Kings College Hospital London
London, , United Kingdom
Site Status
Mortimer Market Centre
London, , United Kingdom
Site Status
Queen Elizabeth Hospital
London, , United Kingdom
Site Status
Royal Free London NHS Foundation Trust
London, , United Kingdom
Site Status
St Marys Hospital
London, , United Kingdom
Site Status
The Royal London Hospital
London, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Belgium
France
Germany
Italy
Spain
United Kingdom
References
Explore related publications, articles, or registry entries linked to this study.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-004040-38
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
NEAT 33
Identifier Type: -
Identifier Source: org_study_id